China Healthcare: Outlook and Opportunities in 2022 with Criss Wang

In this episode, recorded on 16 February 2022, Healthcare Analyst Criss Wang joins us for a deep-dive into China's healthcare sector, exploring investment opportunities, stocks to watch, and general outlook for the year ahead. Stocks mentioned in this episode: Shenzhen Mindray Bio-Medical Electronics (300760 CH) Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436 CH) BeiGene Ltd (6160 HK) Innovent Biologics Inc (1801 HK) Shanghai Junshi Bioscience Co. Ltd. (1877 HK) Remegen Co Ltd (9995 HK) WuXi AppTec Co Ltd (603259 CH) Wuxi Biologics (2269 HK)) -- Follow Criss's work: https://skr.ma/E9jCnmveESxaKicQ7 Smartkarma subscribers can access the presentation slides here: https://skr.ma/Tc214CYti7ymf2dr7 -- Criss Wang is a HK/China Healthcare Analyst with over 13 years of experience in both finance and healthcare, covering clinic operations, investment, and equity research both in China and overseas. This podcast is provided for general informational and entertainment purposes only, and is not intended to provide financial, investment or other professional advice. Views expressed by third parties do not necessarily represent Smartkarma’s views. Smartkarma assumes no responsibility or liability for the accuracy, compliance or completeness of the podcast or the information it contains. Users should not rely on the podcast or the information it contains when making individual, business or other strategic decisions and should always consult a qualified expert or professional adviser.